PH12018502571A1 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer - Google Patents

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Info

Publication number
PH12018502571A1
PH12018502571A1 PH12018502571A PH12018502571A PH12018502571A1 PH 12018502571 A1 PH12018502571 A1 PH 12018502571A1 PH 12018502571 A PH12018502571 A PH 12018502571A PH 12018502571 A PH12018502571 A PH 12018502571A PH 12018502571 A1 PH12018502571 A1 PH 12018502571A1
Authority
PH
Philippines
Prior art keywords
androgens
prostate cancer
treatment
resistant prostate
metastatic castrate
Prior art date
Application number
PH12018502571A
Inventor
Isan Chen
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/061197 external-priority patent/WO2014052237A1/en
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of PH12018502571A1 publication Critical patent/PH12018502571A1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Described herein are anti-androgens for use in treating non-metastatic castrate-resistant prostate cancer
PH12018502571A 2013-09-23 2018-12-06 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer PH12018502571A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2013/061197 WO2014052237A1 (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
US201661705900P 2016-11-26 2016-11-26

Publications (1)

Publication Number Publication Date
PH12018502571A1 true PH12018502571A1 (en) 2020-12-07

Family

ID=74211847

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018502571A PH12018502571A1 (en) 2013-09-23 2018-12-06 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Country Status (1)

Country Link
PH (1) PH12018502571A1 (en)

Similar Documents

Publication Publication Date Title
PH12018502569A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
SG11201510751YA (en) Composition and vaccine for treating prostate cancer
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
HK1217289A1 (en) Compositions and methods for treatment of cancer using bacteria
EP3062808A4 (en) Treatment of metastatic prostate cancer
EA201992251A1 (en) ANTI-CANCER VACCINES AND METHODS OF TREATMENT WITH THEIR APPLICATION
IL242386B (en) Use of eribulin and lenvatinib as combination therapy for treatment of cancer
MX2015006478A (en) Glutamase inhibitors and method of use.
MX2015007185A (en) Use of eribulin in the treatment of breast cancer.
MX2017006015A (en) Apilimod for use in the treatment of renal cancer.
MX2017006026A (en) Apilimod for use in the treatment of colorectal cancer.
MX2015013021A (en) 5-bromo-indirubins.
PT3258931T (en) Use of cabazitaxel in the treatment of prostate cancer
HK1215535A1 (en) Cabazitaxel and its use for treating metastatic prostate cancers
PH12018502571A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
GB201612794D0 (en) Therapeutic use of diethanololeamide in prostate cancer treatment
GB201322958D0 (en) Uses of oligouronates in cancer treatment